InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,733.62
(
0.37%
)
US TECH 100
19,496.40
(
0.29%
)
Dow Jones
41,863.61
(
0.17%
)
Brent Oil
75.72
(
0.81%
)
Bitcoin
69,736.03
(
2.84%
)
Post# of 253531
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: mcbio post# 114853

Tuesday, 02/15/2011 10:05:42 PM

Tuesday, February 15, 2011 10:05:42 PM

Post# of 253531
>>Gralise orphan designation

Although the market didn't like this news, I really think it is of very little practical significance. Orphan designation stops an imitator for 7 years, but Gralise would be very hard indeed to copy because of its unique PK characteristics. (Note that it is labeled as non-substitutable with Neurontin, which in this case is a good feature). So the chance of generic competition is remote in my opinion.

Peter

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up